GUIDELINE-PREFERRED 1L TREATMENT FOR ALK+ NSCLC PATIENTS2,3 Superior survival1 OS rate: 62.5% with ALECENSA vs 45.5% with crizotinib; ALECENSA mOs yet to be reached GUIDELINE-PREFERRED 1L TREATMENT FOR ALK+ NSCLC PATIENTS2,3 Proven efficacy1 mPFS 34.8 months with ALECENSA vs 10.9 months with crizotinib GUIDELINE-PREFERRED 1L TREATMENT FOR ALK+ NSCLC PATIENTS2,3 Click here for more information about how Roche is responding to COVID-19 Questions about our medicines? Visit medinfo.roche.com GUIDELINE-PREFERRED 1L TREATMENT FOR ALK+ NSCLC PATIENTS2,3 5 year OS data Superior survival1 OS rate: 62.5% with ALECENSA vs 45.5% with crizotinib; ALECENSA mOS yet to be reached 5 year OS data Proven efficacy1 mPFS 34.8 months with ALECENSA vs 10.9 months with crizotinib 5 year OS data How Roche is responding to COVID-19 Learn More Questions about our medicines Proven protection Proven Protection Nearly 3 years freedom from progression1 (34.8 months [95% Cl: 17.7, NE]) Learn More Superior survival Superior survival 6/10alive at 5 years1 Learn More Reassuring experience Reassuring experience Long-term safety, tolerability and QoL1,4 Learn More How ALECENSA works How ALECENSA works Discover ALECENSA mechanism of action Learn More Real-world experience Real-world experience Hear patients and experts talk about ALECENSA Learn More Resource centre Resource centre Download SmPC and other resources Learn More Younity Request Medical Information